LX9851 – Talk Bio

Actionable Insights Powered by AI

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

4 weeks ago talkbio0Tagged lexicon, LX9851, Mechanism (attribute), Obesity

Obesity, LX9851, lexicon, Mechanism (attribute)

Lexicon Pharmaceuticals Shifts Focus to Clinical Development Following Zynquista Setbacks

5 months ago talkbio0Tagged (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol, Clinical Development, lexicon, LX9211, LX9851, R&D pipeline, restructuring, United States Food and Drug Administration, Zynquista

Lexicon Pharmaceuticals, Zynquista, FDA, Clinical Development, Restructuring, R&D Pipeline, LX9211, Sotagliflozin, LX9851